Go to deals
Healthcare | Private Equity

Medicharme has sold a majority stake to G Square

Medicharme has completed a growth capital transaction backed by G Square, a UK-based private equity fund dedicated to Healthcare investments.

Medicharme is a French geriatric care facilities operator. It owns 15 long-term care nursing homes in France, with nearly 1,000 beds.

G Square is a British leading healthcare private equity investor, focusing on European mid-market projects with a high potential for growth. G Square provides between US$35–70 million of equity in each healthcare investment deal. the firm will support Medicharme's ambitious development plan to operate 2,500 beds within the next five years.

Oaklins' team in France assisted Medicharme in this transaction.

Parties

Talk to the deal team

 Thibaut  de Monclin

Thibaut de Monclin

Managing Partner
Paris, France
Oaklins France

Related deals

Top Systems teams up with Holland Capital to create the premier Dutch battery-based solutions provider
Private Equity | Energy

Top Systems teams up with Holland Capital to create the premier Dutch battery-based solutions provider

Holland Capital, a Netherlands-based private equity firm, has acquired a stake in Top Systems, a leading provider of complete battery-based power solutions, with a unique value-added services proposition.

Learn more
Infotreasury has been sold to Matera
Private Equity | Financial Services | TMT

Infotreasury has been sold to Matera

Matera, a leading banking software company with world-class instant payments and core banking solutions, has acquired Infotreasury.

Learn more
Thrive Freeze Dry has successfully sealed the acquisition deal with Paradiesfrucht GmbH
Private Equity | Food & Beverage

Thrive Freeze Dry has successfully sealed the acquisition deal with Paradiesfrucht GmbH

Paradiesfrucht GmbH, a gobal freeze dryer of fruits, fruit preparations, drops, powders and granulates, has been acquired by Thrive Freeze Dry (Thrive), a portfolio company of Entrepreneurial Equity Partners (e2p) and Mubadala Capital. The transaction is expected to close in 2024, subject to customary closing conditions, including antitrust approval.

Learn more